Abstracts, Publications, and Presentations
2013 ASH Abstracts
2013 ASCO Abstracts
2012 ASH Abstracts
2011 ASH Abstracts
2010 ASH Abstracts
For a more extensive list of publications visit PubMed.
In addition, physicians and researchers at the UAMS Myeloma Institute for Research and Therapy routinely present at national and international conferences and scientific meetings. To learn more about our findings, please use the links listed below.
Five Gene Probes Carry Most Of The Discriminatory Power Of The 70-Gene Risk Model In Multiple Myeloma
2013 ASH Poster Presentations
Cure of Myeloma
PACMED Salvage Therapy for Advanced High-Risk Multiple Myeloma (AHRMM)
Autotransplants for Multiple Myeloma (MM)
Abnormally High Levels of E- and N-Cadherin Expression Consequences of Intermittent PTH Treatment on Myeloma Growth, Bone Disease and Molecular Profiling of Whole Myelomatous Bone.
Myeloma Cell Interaction with Osteoclasts and Mesenchymal Stem Cells Reveals Genes Associated with Post Relapse Survival.
Gene Expression Profiling (GEP)
Human Placenta-Derived Adherent Cells Stem Cells Primarily Traffic to Mesenteric Lymph Nodes
DKK1 is an Immediate Early Gene in Multiple Myeloma Cells Modulated by Cell Density and IL-6
Improved Outcome with Total Therapy 3 (TT3)
Modeling for the Cure: Total Therapy Trials for Newly Diagnosed Multiple Myeloma: Let the Math Speak!
Confirmed in Successor Protocol Expanded Natural Killer Cells Inhibit Myeloma Tumor Growth in Vivo
Clinical Research in Multiple Myeloma: Linking Outcomes to Genomics of Both Tumor & Normal Host Cells
The Myth of Incurability 90% CR Sustained 4 Years After Onset of CR in Gene Array-Defined Low-Risk Myeloma Treated With Total Therapy 3: Basis for Risk-Adapted TT4 AND TT5
Hematologic Malignancies in the Aging Population: Biology, Molecular Prognostic Markers and Novel Treatment Strategies
Total Therapy for Multiple Myeloma: Evolution from Palliation to Cure during 20 Years of Clinical Research
Listen to Presentations:
Frits van Rhee, MD, PhD Total Therapy program on CurePanel
John Shaughnessy, PhD Towards a Molecular-Based Risk Stratification of Multiple Myeloma
Joshua Epstein, DSc The Scid-hu model for Multiple Myeloma
Bart Barlogie, MD, PhD, Debate II – Should autologous transplant be part of the primary treatment in mm? YES